Napo Pharmaceuticals, Inc.’s Post

Type 2 diabetes is treated with the drug sitagliptin, which is sold under the well-known brand names Januvia and Janumet. Sitagliptin belongs to the class of drugs known as DPP-4 inhibitors. Plaintiffs who suffered from the side effects of Januvia filed many claims against Merck & Co. Courts around the country received the Januvia class action case, which alleged that the pharmaceutical companies had failed to disclose the risk. Plaintiffs in the Januvia pancreatic cancer lawsuit are suing Merck & Co. for payment of medical expenses, funeral expenses, and other damages, alleging that the pharmaceutical company should have known or knew that Januvia might cause this deadly type of cancer. Want to get more information on this? Read the full article here: https://lnkd.in/gzrNwim7 #januvialawsuits #medlegal360

# Only Put Off Until Tomorrow What You Are Willing to Die Having Left Undone ## FDA Approves Lilly's Eczema Drug Ebglyss: A Promising Opportunity for Investors In a significant breakthrough, Eli Lilly and Company \(LLY\) has received FDA approval for its IL-13 inhibitor Ebglyss \(lebrikizumab\) to treat moderate-to-severe atopic dermatitis, commonly known as eczema. This approval covers both adults and children aged 12 and above, weighing at least 40 kgs, who suffer from moderate-to-severe atopic dermatitis. With this positive development, Eli Lilly and Company opens up a promising avenue in the pharmaceutical industry. Ebglyss offers a potential solution for patients seeking effective treatment for their atopic dermatitis symptoms. The FDA's seal of approval is a testament to the drug's safety and efficacy, affirming its potential to meet a critical unmet medical need. As an experienced investment advisor, I firmly believe that seizing opportunities in the healthcare sector can be incredibly rewarding. Investing in companies like Eli Lilly and its groundbreaking innovations allows investors to not only support advancements in healthcare but also secure potentially lucrative returns. Don't miss out on this chance to align your investments with your values while reaping financial rewards. Take action now, open a Health Savings Account \(HSA\) and consider including Eli Lilly and Company in your portfolio. Let's build a future where health, family, and wellness are at the forefront. #HSA #Investing #Healthcare #Health #Family #Wellness 💪💰✨📈

US FDA approves first drug for fatty liver disease https://lnkd.in/g49yQ9kP Key takeaways: 1. The FDA has approved Madrigal Pharmaceuticals' drug for non-alcoholic steatohepatitis (Nash), marking the first treatment for the condition. 2. Nash, now called metabolic dysfunction-associated steatohepatitis (Mash), affects about 1.5 million people in the US. 3. Madrigal PharmaceuticalsPharmaceuticals's oral drug, Rezdiffra, will be available in US from April, priced at an annual wholesale price of US$47,400. 4. The drug has been approved for Nash patients with fibrosis (scarring) in stage two or three severity. 5. Nash is linked to obesity, hypothyroidism, diabetes, and high fat levels in the blood, causing liver fat buildup, inflammation, and fibrosis. #regulatoryaffairs

Baricinix 4mg Baricitinib Baricinix-4mg(Baricitinib) is a prescription medication used to treat rheumatoid arthritis, alopecia areata, and COVID-19 in adults who have not responded well to TNF inhibitors. It works by blocking the activity of Janus kinase (JAK) proteins, reducing inflammation, and improving symptoms, especially in those who require supplemental oxygen or ventilators. Baricinix-4mg(Baricitinib) is manufactured by the Bangladeshi Pharmaceutical BEACON which is a renowned pharmaceutical in Bangladesh. Baricinix-4mg is made under the brand name Olumiant and the generic name is Baricitinib. #rheumetoid_arthritise #Alopecia_areata #Baricitinib #Baricinix_4mg #Buy_Baricinix_Online #Italy #Iran #Egypt #japan #Mexico #Germany #Spain #Australia https://lnkd.in/gMAPEdp7

As part of its ongoing review, the European Medicines Agency this week is slated to examine the potential risks of suicidal ideation and self-harm associated with diabetes and weight-loss treatments. Novo's industry-topping GLP-1 products Wegovy, Ozempic and Rybelsus are part of the review, alongside Lilly's Trulicity and AstraZeneca's Byetta. The EMA launched its investigation into weight-loss treatments in July 2023. At the time, authorities had flagged around 150 cases of self-harm and suicidal ideation that could potentially be linked to the medications. The FDA launched its own review in January but preliminary results showed no link between GLP-1 treatments and suicidal thoughts. #biotech #biopharma #GLP1 #obesity #weightloss #Wegovy #Ozempic

We would like to congratulate Madrigal Pharmaceuticals as "Rezdiffra” as it became the first and only medication approved by the FDA for the treatment of #NASH (also known as “#MASH”) This is a pivotal moment in the treatment of #fattyliverdisease and theTawazun Health team is looking forward to supporting the #earlydetection #earlydiagnosis and #management of #fattyliverdisease around the world with our point-of-care specialist Fibroscan service into any #clinic #clinicaltrials #primarycare what you need, where you need it and when you need it Together we can all reduce the prevalence of liver disease. https://lnkd.in/dU6Ue27h #MASH #NASH #NAFLD #MAFLD #resmetirom #fattyliver #liverdisease #patientcare #patientadvocacy #patientsfirst Louise Campbell

𝐑𝐞𝐠𝐞𝐧𝐞𝐫𝐨𝐧 𝐚𝐧𝐝 𝐒𝐚𝐧𝐨𝐟𝐢 𝐄𝐧𝐡𝐚𝐧𝐜𝐞 𝐃𝐮𝐩𝐢𝐱𝐞𝐧𝐭 𝐋𝐚𝐛𝐞𝐥 𝐟𝐨𝐫 𝐀𝐭𝐨𝐩𝐢𝐜 𝐃𝐞𝐫𝐦𝐚𝐭𝐢𝐭𝐢𝐬 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Regeneron and Sanofi Sanofi announce a label update for Dupixent® (dupilumab) by the U.S. FDA. The update includes efficacy and safety data for patients aged 12 years and older with atopic dermatitis and uncontrolled moderate-to-severe hand and/or foot involvement. These Phase 3 results, the first for this challenging subset, are now part of the EU label, with additional regulatory submissions in progress. “Dupixent is now the first biologic with data in the label supporting its use in this particularly challenging subset of the disease,” says Dr. George D. Yancopoulos george yancopoulos, Co-Chair of the Board and President/Chief Scientific Officer at Regeneron. The label update stems from Phase 3 LIBERTY-AD-HAFT trial data, where Dupixent showed significant improvements: Primary Endpoint: 40% achieved clear or almost clear skin on hands and feet compared to 17% with placebo. Key Secondary Endpoint: 52% experienced a clinically meaningful reduction in itch on hands and feet compared to 14% with placebo. Safety results align with Dupixent’s known profile in atopic dermatitis. The LIBERTY-AD-HAFT trial included 133 patients with moderate-to-severe hand and/or foot involvement. The primary endpoint assessed clear or almost clear skin at 16 weeks, and the key secondary endpoint measured itch reduction. #AtopicDermatitis #Dupixent #FDAApproval #SkinHealth #MedicalInnovation #Regeneron #Sanofi

The FDA on Monday signed off on Liquida Corporation’s Yutrepia (nebulized treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. However, the regulator’s tentative approval means that Yutrepia cannot yet enter the U.S. market—despite meeting all regulatory standards of safety, quality and efficacy. Liquida must wait out the existing regulatory exclusivity of a competing product from United Therapeutics. The biopharma expects that the FDA will be able to grant traditional approval after May 23, 2025. Despite the regulatory victory, investors were disappointed by the tentative approval. Liquida’s shares dropped by almost 40% in pre-market trading on Monday. #biotech #biopharma #pharma

FDA expands J&J's psoriasis drug for inflammatory bowel disease J&J has been betting on Tremfya, as its other blockbuster drug for psoriasis and ulcerative colitis, Stelara, is looking at a patent cliff - which occurs when a company loses its patent protection, allowing cheaper biosimilars to enter the market. #chronicinflammatoryboweldisease I #Biosimilars I #expandeduse I #protein I #inflammatoryboweldiseases I Johnson & Johnson Read more: https://lnkd.in/gP_jVZxa

Today Ironwood Pharmaceuticals reported topline Phase 3 of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF). Apraglutide is a long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome (SBS). Ironwood plans to submit a new drug application (NDA) and other regulatory filings for apraglutide for use in adult patients with SBS who are dependent on PS. Currently, Takeda’s Gattex (teduglutide) is the only approved GLP-2 analog and requires once-daily subcutaneous injection. More options would be good for SBS patients. Under a joint collaboration, OPKO will supply its proprietary long-acting GLP-2 peptide to combine with Entera’s oral peptide platform for the development of the first potential daily oral GLP-2 for the treatment of short bowel syndrome. Pre-IND data for oral GLP-2 tablets using Entera’s N-Tab technology is expected in H1 2024. https://lnkd.in/gv5B6sQ4 #ShortBowelSyndrome #shortgut #healthcare #SBS #GLP2 #rarediseases #rarediseaseday #rarediseaseday2024 #rarediseaseawareness #shortgutsowhat #sbsawareness #shortgut